Izalontamab SI-B001 is an exciting advance in the management of difficult-to-treat multiple myeloma. The innovative antibody directly interacts with BCMA on myeloma tumors, inducing antibody-dependent cellular https://izalontamab-supplier517095.pointblog.net/izalontamab-si-b001-a-hopeful-new-antibody-therapy-97080388